Antibody-Drug Conjugates Development
Targeted therapeutics, including antibody-drug conjugates (ADCs) and polymer-drug conjugates, represent a growing segment of therapeutic molecules in development. ADCs combine the targeting specificity of monoclonal antibodies (mAbs) with the highly potent cytotoxic properties of small molecules for the treatment of cancer. For ADCs, the cytotoxic payload is attached to the mAb via a covalent linkage; however, despite advances in protein engineering, the resultant conjugate is highly heterogeneous. The intrinsic heterogeneity significantly affects the complexity of the discovery and development pathway. Because Wolfe Laboratories has extensive expertise in the development of both small molecules and biologics and an active basic research program in ADCs, the Wolfe Laboratories team possesses extraordinary experience and capabilities in the development of ADCs and other polymer-drug conjugates. A summary of Wolfe Laboratories’ capabilities is provided below.
Wolfe Laboratories’ integrated capabilities for development of antibody-drug conjugates